Lupus Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Lupus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 68 trials

Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled33 locationsNCT06916806
Recruiting
Phase 1

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

Systemic Lupus Erythematosus
GlaxoSmithKline54 enrolled3 locationsNCT07371468
Recruiting
Phase 2

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

COVID-19Inflammatory Bowel DiseaseRheumatoid Arthritis (RA)+5 more
McGill University Health Centre/Research Institute of the McGill University Health Centre660 enrolled3 locationsNCT06599658
Recruiting

Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+2 more
Cairo University460 enrolled1 locationNCT07277491
Recruiting
Phase 1

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

Rheumatoid ArthritisSystemic Lupus Erythematosus
Merck Sharp & Dohme LLC21 enrolled3 locationsNCT07363590
Recruiting
Early Phase 1

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

Sjogren's SyndromeAutoimmune DiseasesIdiopathic Inflammatory Myopathies+3 more
Nanjing Bioheng Biotech Co., Ltd.20 enrolled1 locationNCT06548607
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1Phase 2

Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947473
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1Phase 2

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Beijing GoBroad Hospital45 enrolled1 locationNCT06947460
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting
Phase 2

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled52 locationsNCT06570798
Recruiting
Phase 1

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Rheumatoid ArthritisSystemic Lupus Erythematosus
AstraZeneca48 enrolled19 locationsNCT07201558
Recruiting
Not Applicable

Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)

Rheumatoid ArthritisSclerodermaSystemic Lupus Erythematosus
Shenzhen MagicRNA Biotechnology Co., Ltd30 enrolled1 locationNCT06801119
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting
Phase 1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Multiple SclerosisRheumatoid Arthritis (RA)Dermatomyositis+4 more
Kyverna Therapeutics70 enrolled1 locationNCT07403188
Recruiting
Phase 1

DR-0201 in Subjects With Autoimmune Diseases

SclerodermaSLEDermatomyositis+9 more
Dren Bio36 enrolled10 locationsNCT06647069